All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1336 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.B11.B6), pCDTCR1 | T4.1.B11.B6 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1337 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.B4), pCDTCR1 | T4.1.B4 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1338 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.C11b), pCDTCR1 | T4.1.C11b | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1339 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.C2), pCDTCR1 | T4.1.C2 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1340 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.D5), pCDTCR1 | T4.1.D5 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1341 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.D7.E5), pCDTCR1 | T4.1.D7.E5 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1342 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.F10.G4), pCDTCR1 | T4.1.F10.G4 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1343 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.F9), pCDTCR1 | T4.1.F9 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1344 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.G11), pCDTCR1 | T4.1.G11 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1345 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.1.G2), pCDTCR1 | T4.1.G2 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1346 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.2.E8), pCDTCR1 | T4.2.E8 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1347 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.2.F7), pCDTCR1 | T4.2.F7 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1348 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.2.G11), pCDTCR1 | T4.2.G11 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1349 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.2.G2.C11), pCDTCR1 | T4.2.G2.C11 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1350 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.2.G6), pCDTCR1 | T4.2.G6 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1351 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.3.B.10), pCDTCR1 | T4.3.B.10 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1352 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.3.B3.B7), pCDTCR1 | T4.3.B3.B7 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1353 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.3.B5), pCDTCR1 | T4.3.B5 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector | ||
TCR-YC1354 | Mouse anti-VITAFT(α-D-GalNAc)EGLK T cell receptor (T4.3.B7), pCDTCR1 | T4.3.B7 | Mouse | VITAFTEGLK + GLYC(T6) | H2 class II Eᵏ | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION